Advertisement


Ruth O’Regan, MD, and Ann H. Partridge, MD, on The NRG Oncology/NSABP B-42, IDEAL, and DATA Studies

2016 San Antonio Breast Cancer Symposium

Advertisement

Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings from a session Dr. O’Regan moderated on three major trials addressing anastrozole after tamoxifen in HR-positive early breast cancer, letrozole in HR-positive disease, and extended letrozole treatment after adjuvant endocrine therapy (Abstracts S1-03, S1-05, S1-08).



Related Videos

Breast Cancer

Eric P. Winer, MD: The McGuire Lecture

Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.

Breast Cancer

Sara A. Hurvitz, MD, on HR-Positive, HER2-Negative Breast Cancer: Results of the neoMONARCH Trial

Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses findings on the biological effects of abemaciclib in a neoadjuvant study for postmenopausal patients (A...

Breast Cancer
Issues in Oncology

Jennifer K. Litton, MD, and Ann H. Partridge, MD, on Breast Cancer in Young Women

Jennifer K. Litton, MD, of MD Anderson Cancer Center, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss a range of issues for young women with br...

Breast Cancer

Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatin...

Breast Cancer
Genomics/Genetics

Nikhil Wagle, MD, on Breast Cancer: Advances in Genomics

Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications fo...

Advertisement

Advertisement



Advertisement